Innovation moves faster when innovators understand where strategic demand already exists.
On May 12, Triple Ring will host the 2026 U.S.–Japan Healthcare Connection Reverse Pitch Event in Newark, California, bringing together Japanese pharmaceutical leaders, strategic investors, and U.S. healthcare innovators for an evening focused on partnership, investment priorities, and cross-border collaboration.
Hosted in collaboration with the Japan Society of Northern California and Biocom California, the event continues a growing effort to strengthen connections between the U.S. and Japanese healthcare innovation ecosystems.
Unlike traditional startup pitch events, the reverse pitch format shifts the conversation.
Instead of startups presenting first, strategic partners and healthcare leaders take the stage to share:
- Investment priorities
- Partnership interests
- Therapeutic focus areas
- Market opportunities
- Unmet industry needs
The goal is simple: create stronger alignment between innovators and the organizations actively seeking new technologies, platforms, and partnerships.
Why Reverse Pitch Matters
For many early-stage healthcare companies, one of the biggest challenges isn’t developing technology, it’s identifying the right fit with strategic partners.
Reverse pitch events help remove that ambiguity.
By hearing directly from pharmaceutical companies, corporate venture groups, and investors, innovators gain clearer visibility into the technologies and therapeutic areas attracting attention across the global healthcare landscape.
This year’s participating organizations include:
- AN Ventures
- Astellas Venture Management
- Chugai Pharma USA
- Daiichi Sankyo
- Nippon Life Global Investors
- Ono Venture Investment
- Recor Medical
The event also features a panel discussion on “Why Do Therapeutics in Japan?”.
The conversation will examine market-entry strategy, partnership dynamics, and the opportunities available to companies looking to expand within the Japanese healthcare market.
Building Cross-Border Innovation Pathways
Japan and the United States each bring distinct strengths to healthcare innovation.
Japan continues to play a major role in pharmaceuticals, long-term healthcare investment, and global commercialization infrastructure. The U.S. remains a leading hub for emerging biotech, therapeutics, and startup-driven innovation.
Events like the U.S.–Japan Healthcare Connection Reverse Pitch create opportunities to connect these complementary strengths in more intentional ways – bringing investors, strategics, and innovators into direct conversation around shared priorities.
Building on the momentum of the 2025 Medtech and Diagnostics Reverse Pitch, this year’s event brings a more focused lens to biopharma and therapeutics, reflecting the evolving priorities of global healthcare innovation.
This year’s program also marks an important milestone for the series itself.
The 2026 event is the sixth Reverse Pitch event hosted through the U.S.–Japan Healthcare Connection initiative, following the successful Medtech and Diagnostics Reverse Pitch event held at Triple Ring in November 2025.
Where Collaboration Turns Into Momentum
At Triple Ring, we believe meaningful innovation happens when technical expertise, strategic insight, and the right partnerships come together around clearly defined challenges.
Hosting the U.S.–Japan Healthcare Connection Reverse Pitch Event reflects that philosophy.
The event creates space for conversations that move beyond networking and toward actionable collaboration, connecting healthcare innovators with organizations shaping the future of therapeutics, investment, and global healthcare partnerships.
Because breakthrough innovation happens when the right people come together around the right opportunities.
Event Details
2026 U.S.–Japan Healthcare Connection Reverse Pitch Event, hosted in collaboration with the Japan Society of Northern California and Biocom California.
Date: Tuesday, May 12, 2026
Time: 4:00 PM – 6:30 PM PT
Location: Triple Ring, 39655 Eureka Dr, Newark, CA 94560
